Susquehanna International Group
KPTI icon

Susquehanna International Group’s Karyopharm Therapeutics KPTI Stock Holding History

Susquehanna International Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$134K Sell
24,138
-123,560
-84% -$942K ﹤0.01% 12120
2025
Q4 		$1.09M Buy
147,698
+112,359
+318% +$687K ﹤0.01% 6990
2025
Q3 		$231K Buy
+35,339
New +$190K ﹤0.01% 10675
2025
Q2 		– Sell
-11,548
Closed -$56.7K – 13232
2025
Q1 		$43.2K Sell
11,548
-32,728
-74% -$279K ﹤0.01% 11906
2024
Q4 		$449K Buy
44,276
+24,106
+120% +$291K ﹤0.01% 8949
2024
Q3 		$251K Sell
20,170
-9,395
-32% -$117K ﹤0.01% 9999
2024
Q2 		$385K Buy
29,565
+24,458
+479% +$405K ﹤0.01% 8885
2024
Q1 		$116K Sell
5,107
-133
-3% -$2.33K ﹤0.01% 11122
2023
Q4 		$68K Sell
5,240
-3,947
-43% -$53.2K ﹤0.01% 11566
2023
Q3 		$185K Buy
9,187
+3,253
+55% +$73K ﹤0.01% 10317
2023
Q2 		$159K Sell
5,934
-13,745
-70% -$592K ﹤0.01% 10516
2023
Q1 		$1.15M Buy
19,679
+2,666
+16% +$132K ﹤0.01% 6451
2022
Q4 		$868K Sell
17,013
-9,115
-35% -$632K ﹤0.01% 6497
2022
Q3 		$2.14M Buy
26,128
+7,332
+39% +$548K ﹤0.01% 4782
2022
Q2 		$1.27M Buy
18,796
+54
+0.3% +$4.95K ﹤0.01% 5932
2022
Q1 		$2.07M Sell
18,742
-21,446
-53% -$2.67M ﹤0.01% 5389
2021
Q4 		$3.88M Buy
40,188
+4,162
+12% +$415K ﹤0.01% 4184
2021
Q3 		$3.15M Buy
36,026
+14,486
+67% +$1.5M ﹤0.01% 4855
2021
Q2 		$3.33M Buy
21,540
+1,176
+6% +$171K ﹤0.01% 4794
2021
Q1 		$3.21M Sell
20,364
-6,378
-24% -$1.34M ﹤0.01% 4798
2020
Q4 		$6.21M Buy
26,742
+11,349
+74% +$2.63M ﹤0.01% 3103
2020
Q3 		$3.37M Sell
15,393
-21,565
-58% -$5.27M ﹤0.01% 3668
2020
Q2 		$10.5M Buy
36,958
+29,628
+404% +$8.76M ﹤0.01% 2074
2020
Q1 		$2.11M Buy
+7,330
New +$2.02M ﹤0.01% 3881
2019
Q4 		– Sell
-3,635
Closed -$789K – 10198
2019
Q3 		$524K Sell
3,635
-519
-12% -$70.4K ﹤0.01% 7212
2019
Q2 		$373K Sell
4,154
-33,049
-89% -$2.65M ﹤0.01% 7878
2019
Q1 		$3.26M Buy
37,203
+32,780
+741% +$3.63M ﹤0.01% 3015
2018
Q4 		$622K Buy
+4,423
New +$746K ﹤0.01% 5608
2018
Q1 		– Sell
-3,166
Closed -$631K – 9777
2017
Q4 		$456K Sell
3,166
-568
-15% -$91.2K ﹤0.01% 6816
2017
Q3 		$615K Buy
3,734
+1,907
+104% +$273K ﹤0.01% 6167
2017
Q2 		$248K Buy
1,827
+95
+5% +$14.1K ﹤0.01% 7927
2017
Q1 		$334K Sell
1,732
-834
-33% -$134K ﹤0.01% 7171
2016
Q4 		$362K Buy
2,566
+1,556
+154% +$210K ﹤0.01% 7610
2016
Q3 		$147K Sell
1,010
-337
-25% -$40.5K ﹤0.01% 7782
2016
Q2 		$136K Buy
1,347
+152
+13% +$19.7K ﹤0.01% 7870
2016
Q1 		$160K Sell
1,195
-917
-43% -$101K ﹤0.01% 8162
2015
Q4 		$420K Sell
2,112
-2,401
-53% -$520K ﹤0.01% 7097
2015
Q3 		$713K Buy
4,513
+2,196
+95% +$587K ﹤0.01% 6426
2015
Q2 		$946K Sell
2,317
-600
-21% -$259K ﹤0.01% 6338
2015
Q1 		$1.34M Buy
2,917
+1,949
+201% +$840K ﹤0.01% 5171
2014
Q4 		$544K Buy
+968
New +$550K ﹤0.01% 7052

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Susquehanna International Group's KPTI Position: Q1 2026 in Review

Susquehanna International Group reduced its Karyopharm Therapeutics (KPTI) stake by 84% in Q1 2026, selling an estimated $942K and leaving 24,138 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #12120.

Susquehanna International Group first reported a position in KPTI in Q4 2014 and has held it in 41 quarters since. The position peaked at $10.5M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Susquehanna International Group held 24,138 shares of Karyopharm Therapeutics worth $134K as of Q1 2026.
  • Susquehanna International Group sold 123,560 Karyopharm Therapeutics shares in Q1 2026, an estimated $942K.
  • Karyopharm Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12120 holding.
  • Susquehanna International Group first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 41 quarters since.
  • Susquehanna International Group's Karyopharm Therapeutics position peaked at $10.5M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.